Research Progress in Effects of Gene Polymorphism on Analgesic Drug Treatment for Neuropathic Pain
LIU Lei1,2, LI Wen-ting2, WANG Lai-yin1, LI Yu-zhen2, FENG Zhi-ying1, RAO Yue-feng1*
1. Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; 2. Department of Pharmacy, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China
Abstract：With the proposal of the conception precision medication, the influence of gene polymorphism on the efficacy of drugs has drawn widespread attention. Genetic testing has recently become an important strategy to evaluate drug efficacy and prevent adverse drug reactions. Clinical medication practice has proved that the therapeutic effects of analgesics under the traditional empirical medication model have significant individual differences. This article reviews the individualized therapeutic effects of neuropathic pain analgesics based on genetic polymorphisms, aiming to provide a clinical guidance for the safe and rational application of analgesics as well as a scientific evidence for the department of pharmacy to carry out drug genetic testing.
刘蕾, 李雯婷, 王莱茵, 李玉珍, 冯智英, 饶跃峰. 基因多态性对镇痛药物治疗神经病理性疼痛疗效的研究进展[J]. 中国药学杂志, 2022, 57(9): 677-683.
LIU Lei, LI Wen-ting, WANG Lai-yin, LI Yu-zhen, FENG Zhi-ying, RAO Yue-feng. Research Progress in Effects of Gene Polymorphism on Analgesic Drug Treatment for Neuropathic Pain. Chinese Pharmaceutical Journal, 2022, 57(9): 677-683.
BANNISTER K, SACHAU J, BARON R, et al. Neuropathic pain: Mechanism-based therapeutics [J]. Annu Rev Pharmacol Toxicol, 2020, 60:257-274.
[2]
SMITH S J, EWAN. Advances in understanding nociception and neuropathic pain [J]. J Neurol, 2018, 265(2):231-238.
[3]
HEHN C A V, BARON R, WOOLF C J. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms [J]. Neuron, 2012, 73(4):638-652.
[4]
JI R R, NACKLEY A V, HUH Y, et al. Neuroinflammation and central sensitization in chronic and widespread pain [J]. Anesthesiology, 2018, 129(2):343-366.
[5]
FINNERUP N B, SINDRUP S H, JENSEN T S. The evidence for pharmacological treatment of neuropathic pain [J]. Pain, 2010, 150(3):573-581.
[6]
SAGHEDDU C, MELIS M. Individual differences and vulnerability to drug addiction: a focus on the endocannabinoid system [J]. CNS Neurol Disord Drug Targets, 2015, 14(4):502-517.
[7]
HAUSER A S, CHAVALI S, MASUHO I, et al. Pharmacogenomics of GPCR drug targets [J]. Cell, 2018, 172(1-2):41-54.
[8]
LAUSCHKE V M, INGELMAN-SUNDBERG M. Prediction of drug response and adverse drug reactions: From twin studies to next generation sequencing [J]. Eur J Pharm Sci, 2019, 130(2019):65-77.
[9]
LEE J, YOO H D, BAE J W, et al. Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6 [J]. Drug Des Dev Ther, 2019, 13:1751-1761.
[10]
RYU S, PARK S, LEE J H, et al. A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans [J]. CTS Clin Transl Sci, 2017, 10(2):93-101.
[11]
HSIAO Y H, HUI R C, WU T, et al. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations [J]. J Dermatol Sci, 2014, 73(2):101-109.
[12]
MCCORMACK M, ALFIREVIC A, BOURGEOIS S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans [J]. N Engl J Med, 2011, 364(12):1134-1143.
[13]
MILISZEWSKI M A, KIRCHHOF M G, SIKORA S, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: An analysis of triggers and implications for improving prevention [J]. Am J Med, 2016, 129(11):1221-1225.
[14]
CHUNG W H, HUNG S I, HONG H S, et al. Medical genetics: a marker for Stevens-Johnson syndrome [J]. Nature, 2004, 428(6982):486. DOI:10.1038/428486a.
[15]
HE X J, JIAN L Y, HE X L, et al. Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China [J]. Pharmacol Rep, 2013, 65(5):1256-1262.
[16]
CHEN P, LIN J J, LU C S, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan [J]. N Engl J Med, 2011, 364(12):1126-1133.
[17]
DEVI K. The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population [J]. Int J Dermatol, 2018, 57(1):70-73.
[18]
WANG L B, CHENB, SUN W L, et al. Carbamazepine induced severe epispasis in two patients and their HLA-B*1502 allele detection[J]. Chin Pharm J(中国药学杂志), 2010,45(19):1513-1515.
[19]
ZHANG Y, WANG J, ZHAO L M, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients [J]. Eur J Clin Pharmacol, 2011, 67(9):885-887.
[20]
CHANG C C, TOO C L, MURAD S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population[J]. Int J Dermatol, 2011, 50(2):221-224.
[21]
TASSANEEYAKUL W, TIAMKAO S, JANTARAROUNGTONG T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population [J]. Epilepsia, 2010, 51(5):926-930.
[22]
KHOR A H, LIM K S, TAN C T, et al. HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis [J]. Epilepsia, 2014, 55(11):e120-e124.
[23]
ZHOU Y, KREBS K, MILANI L, et al. Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing [J]. Clin Pharmacol Ther, 2021, 109(1):160-174.
[24]
KIM S H, LEE K W, SONG W J, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans [J]. Epilepsy Res, 2011, 97(1-2):190-197.
[25]
CHOI H, MOHIT B. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States [J]. Epilepsia, 2019, 60(7):1472-1481.
[26]
AMSTUTZ U, SHEAR N H, RIEDER M J, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions [J]. Epilepsia, 2014, 55(4):496-506.
[27]
OZEKI T, MUSHIRODA T, YOWANG A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population [J]. Hum Mol Genet, 2011, 20(5):1034-1041.
[28]
YIP V L, PIRMOHAMED M. The HLA-A*31:01 allele: influence on carbamazepine treatment [J]. Pharmacogenomics Pers Med, 2017, 10:29-38.
[29]
PHILLIPS E J, SUKASEM C, WHIRL-CARRILLO M, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update clinical pharmacology and therapeutics [J]. Clin Pharmacol Ther, 2018, 103(4):574-581.
[30]
AMSTUTZ U, ROSS C J, CASTRO-PASTRANA L I, et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children [J]. Clin Pharmacol Ther, 2013, 94(1):142-149.
[31]
ZHOU M, CHEN N, HE L, et al. Oxcarbazepine for neuropathic pain [J]. Cochrane Database Syst Rev, 2017, 12(12):Doi:10.1002/14651858.CD007963.
[32]
CHEN M, YANG B, WANG C, et al. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype [J]. Australas J Dermatol, 2016, 57(4):e137-e138.
[33]
DUEHMKE R M, DERRY S, WIFFEN P J, et al. Tramadol for neuropathic pain in adults [J]. Cochrane Database Syst Rev, 2017, 6(6):CD003726.
[34]
ZEBALA J A, SEARLE S L, WEBSTER L R, et al. Desmetramadol has the safety and analgesic profile of tramadol without its metabolic liabilities: Consecutive randomized, double-blind, placebo-and active comparator-controlled trials [J]. J Pain, 2019, 20(10):1218-1235.
[35]
NOFZIGER C, TURNER A J. Pharm var gene focus: CYP2D6 [J]. Clin Pharmacol Ther, 2020, 107(1):154-70.
[36]
MIOTTO K, CHO A K, KHALIL M A, et al. Trends in tramadol: Pharmacology, metabolism, and misuse [J]. Anesth Analg, 2017, 124(1):44-51.
[37]
SMITH D M, WEITZEL K W, ELSEY A R, et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial [J]. Genet Med, 2019, 21(8):1842-1850.
[38]
SMITH E C. Understanding CYP2D6 and its role in tamoxifen metabolism [J]. Oncol Nurs Forum, 2013, 40(6):547-548.
[39]
MEHRPOUR O. Addiction and seizure ability of tramadol in high-risk patients [J]. Indian J Anaesth, 2013, 57(1):86-87.
[40]
NIWA T, YANAI M, MATSUMOTO M, et al. Effect of cytochrome P450 (CYP) 2D6 genetic polymorphism on the inhibitory action of antidepressants on CYP2D6-mediated dopamine formation from p-tyramine [J]. J Pharm Pharm Sci, 2018, 21(1):135-142.
[41]
DONG H, LU S J, ZHANG R, et al. Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients [J]. Eur J Clin Pharmacol, 2015, 71(6):681-686.
[42]
SMITH D M, WEITZEL K W, ELSEY A R, et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial [J]. Genet Med, 2019, 21(8):1842-1850.
[43]
QI G, YIN S, ZHANG G, et al. Genetic and epigenetic polymorphisms of eNOS and CYP2D6 in mainland Chinese Tibetan, Mongolian, Uygur, and Han populations[J]. pharmacogenomics J, 2020, 20(1):114-125.
[44]
KUMAR P, RAI V. Catechol-O-methyltransferase gene Val158Met polymorphism and obsessive compulsive disorder susceptibility: a meta-analysis [J]. Metab Brain Dis, 2020, 35(2):241-251.
[45]
TANG Z, ZHANG S, GUO D, et al. Association between COMT gene Val108/158Met and antidepressive treatment response: A meta-analysis [J]. Gene, 2020, 734:144333.
[46]
SERRANO J M, BANKS J B, FAGAN T J, et al. The influence of Val158Met COMT on physiological stress responsivity [J]. Stress, 2019, 22(2):276-279.
[47]
REN X, ZHANG L, XIAO Q, et al. Association between COMT polymorphism, labor anxiety, and analgesia in pregnant women [J]. J Pain Res, 2019, 12:779-785.
[48]
NIELSEN L M, OLESEN A E, SATO H, et al. Association between gene polymorphisms and pain sensitivity assessed in a multi-modal multi-tissue human experimental model-an explorative study [J]. Basic Clin Pharmacol Toxicol, 2016, 119(4):360-366.
[49]
HOOTEN W M, BIERNACKA J M, O′BRIEN T G, et al. Associations of catechol-O-methyltransferase (rs4680) single nucleotide polymorphisms with opioid use and dose among adults with chronic pain [J]. Pain, 2019, 160(1):263-268.
[50]
ZHANG F, TONG J, HU J, et al. COMT gene haplotypes are closely associated with postoperative fentanyl dose in patients [J]. Anesth Analg, 2015, 120(4):933-940.
[51]
CRIST R C, BERRETTINI W H. Pharmacogenetics of OPRM1 [J]. Pharmacol Biochem Behav, 2014, 123:25-33.
[52]
ZHANG X, LIANG Y, ZHANG N, et al. The relevance of the OPRM1 118A>G genetic variant for opioid requirement in pain treatment: A meta-analysis [J]. Pain Physician, 2019, 22(4):331-340.
[53]
PETTINI E, MICAGLIO M, BITOSSI U, et al. Influence of OPRM1 polymorphism on postoperative pain after intrathecal morphine administration in italian patients undergoing elective cesarean section [J]. Clin J Pain, 2018, 34(2):178-181.
[54]
CHEN L K, CHEN S S, HUANG C H, et al. Polymorphism of μ-opioid receptor gene (OPRM1:c.118A>G) might not protect against or enhance morphine-induced nausea or vomiting [J]. Pain Res Treat, 2013, 2013:259306. Doi:10.1155/2013/259306.
[55]
LIANG J, LIU X, PAN M, et al. Blockade of Nav1.8 currents in nociceptive trigeminal neurons contributes to anti-trigeminovascular nociceptive effect of amitriptyline [J]. Neuromol Med, 2014, 16(2):308-321.
[56]
KOH A, PAK K C, CHOI H Y, et al. Quantitative modeling analysis demonstrates the impact of CYP2C19 and CYP2D6 genetic polymorphisms on the pharmacokinetics of amitriptyline and its metabolite, nortriptyline [J]. J Clin Pharmacol, 2019, 59(4):532-540.
[57]
HICKS J K, SANGKUHL K, SWEN J J, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update [J]. Clin Pharmacol Ther, 2017, 102(1):37-44.
[58]
SIENKIEWICZ-OLESZKIEWICZ B, WIELA-HOJESKA A. CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs [J]. Pharmazie, 2018, 73(11):619-624.
[59]
LI M, ZHOU L J, ZHAN F, et al. Based on CYP2C19 genotype ofclopidogrel and ticagrelortreatment of acute coronary syndromes individualized drug analysis [J]. Chin Pharm J(中国药学杂志), 2019,54(9):753-760.
[60]
WEIDE J V D, BAALEN-BENEDEK E H V, KOOTSTRA-ROS J E. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype [J]. Ther Drug Monit, 2005, 27(4):478-483.
[61]
PERRY P J, ZEILMANN C, ARNDT S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response [J]. J Clin Psychopharmacol, 1994, 14(4):230-240.
[62]
STEIMER W, ZÖPF K, VON AMELUNXEN S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers [J]. Clin Chem, 2004, 50(9):1623-1633.
[63]
SHAHEEN A, ALAM S M, AZAM F, et al. Influence of single nucleotide polymorphism of LAT1 on therapeutic response to gabapentinoids in Pakistani patients with neuropathic pain [J]. Basic Clin Pharmacol Toxicol, 2021, 128(3):503-510.
[64]
LUNN M P, HUGHES R A, WIFFEN P J. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia [J]. Cochrane Database Syst Rev, 2014 (1):Doi:10.1002/14651858.CD007115.pub3.
[65]
CHEN J D, XU X Z, CHEN B B. Association of CYP1A2 and CYP2D6 gene polymorphism with therapeutic efficacy of duloxetine on depression in southern region of Fujian[J]. Chin J Behav Med Brain Sci(中华行为医学与脑科学杂志), 2015, 24(12):1090-1093.
[66]
PERLIS R H, FIJAL B, ADAMS D H, et al. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder [J]. Biol Psychiatry. 2009, 65(9):785-791.
[67]
PILOTTO A, FRANCESCHI M, VITALE D F. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs [J]. Aliment Pharmacol Ther, 2005, 22(2):147-155.
[68]
OCHOA D, PRIETO-PÉREZ R, ROMÁN M, et al. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers [J]. Pharmacogenomics, 2015, 16(9):939-948.
2022, Vol. 57 
